Apo-sucralfate en es it fr

Apo-sucralfate Brand names, Apo-sucralfate Analogs

Apo-sucralfate Brand Names Mixture

  • No information avaliable

Apo-sucralfate Chemical_Formula

C13H10N2O4

Apo-sucralfate RX_link

http://www.rxlist.com/cgi/generic2/thalidom.htm

Apo-sucralfate fda sheet

Apo-sucralfate FDA

Apo-sucralfate msds (material safety sheet)

Apo-sucralfate MSDS

Apo-sucralfate Synthesis Reference

No information avaliable

Apo-sucralfate Molecular Weight

258.23 g/mol

Apo-sucralfate Melting Point

270 oC

Apo-sucralfate H2O Solubility

545 mg/L

Apo-sucralfate State

Solid

Apo-sucralfate LogP

-0.146

Apo-sucralfate Dosage Forms

Tablets for oral administration (50 mg); Capsules for oral administration (50 mg, 100 mg and 200 mg)

Apo-sucralfate Indication

For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.

Apo-sucralfate Pharmacology

Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic — it contains both left and right handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans.

Apo-sucralfate Absorption

The absolute bioavailability has not yet been characterized in human subjects due to its poor aqueous solubility. In studies of both healthy volunteers and subjects with Hansen’s disease, the mean time to peak plasma concentrations (Tmax) ranged from 2.9 to 5.7 hours indicating that thalidomide is slowly absorbed from the gastrointestinal tract.

Apo-sucralfate side effects and Toxicity

The R-configuration and the S-configuration are more toxic individually than the racemic mixture. The LD50 could not be established in mice for racemic thalidomide, whereas LD50 values for the R and S configurations are reported to be 0.4 to 0.7 g/kg and 0.5 to 1.5 g/kg, respectively.

Apo-sucralfate Patient Information

Apo-sucralfate Organisms Affected

Humans and other mammals